Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2009 1
2011 2
2016 2
2018 3
2019 2
2021 5
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Accès précoce aux produits de santé en France : des avancées majeures du CSIS (Conseil stratégique des industries de santé) à concrétiser (modalités, réglementations, financements).
Albin N, Chassagnol F, Bergmann JF; Les participants à la table ronde « Aspects organisationnels et réglementaires » des Ateliers de Giens XXXIV; avec la collaboration de. Albin N, et al. Therapie. 2019 Feb;74(1):87-101. doi: 10.1016/j.therap.2018.11.009. Epub 2018 Dec 6. Therapie. 2019. PMID: 30612729 French. No abstract available.
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, Vincent-Salomon A, Laki F, Boudali L, Raizonville L, Mosseri V, Jochem A, Eeckhoutte A, Diallo M, Stern MH, Fourquet A, Kirova Y. Loap P, et al. Among authors: boudali l. JAMA Oncol. 2022 Dec 1;8(12):1802-1808. doi: 10.1001/jamaoncol.2022.5074. JAMA Oncol. 2022. PMID: 36301572 Free PMC article. Clinical Trial.
Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.
Pham FY, Jacquet E, Taleb A, Monard A, Kerouani-Lafaye G, Turcry F, Brunel L, Grudé F, Yoldjian I, Sainte-Marie I, Boudali L, Blay JY, Albin N. Pham FY, et al. Among authors: boudali l. Int J Cancer. 2022 Oct 15;151(8):1345-1354. doi: 10.1002/ijc.34129. Epub 2022 Jul 7. Int J Cancer. 2022. PMID: 35603979 Free PMC article.
Evaluation of Clinical Trials in Onco-haematology: A New Method Based on Risk Analysis and Multidisciplinarity.
Lapière J, Christen C, Kerouani-Lafaye G, Monard A, Turcry F, Grude F, Gazin V, Burbank M, Chocarne P, Taleb A, Belgodere L, Brunel L, Chu C, Deligny C, Ake E, Gonçalves S, Bouheret P, Barbou-des-Courières S, Sainte-Marie I, Guyader G, Boudali L, Albin N. Lapière J, et al. Among authors: boudali l. Ther Innov Regul Sci. 2021 May;55(3):601-611. doi: 10.1007/s43441-020-00256-7. Epub 2021 Jan 27. Ther Innov Regul Sci. 2021. PMID: 33502745
Response to the letter to the Editor by Professors Francesco Giammarile and Stefano Fanti regarding our article "Survey by the ANSM of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT".
Chevalme YM, Boudali L, Janier M, Talbot JN. Chevalme YM, et al. Among authors: boudali l. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2692-2695. doi: 10.1007/s00259-021-05393-1. Eur J Nucl Med Mol Imaging. 2021. PMID: 34056666 Free PMC article. No abstract available.
At-risk phenotype of neurofibromatose-1 patients: a multicentre case-control study.
Sbidian E, Bastuji-Garin S, Valeyrie-Allanore L, Ferkal S, Lefaucheur JP, Drouet A, Brugière P, Vialette C, Combemale P, Barbarot S, Wolkenstein P; NF France Network. Sbidian E, et al. Orphanet J Rare Dis. 2011 Jul 13;6:51. doi: 10.1186/1750-1172-6-51. Orphanet J Rare Dis. 2011. PMID: 21752287 Free PMC article.
17 results